|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Founded: November 2003
Ownership: Publicly traded on AiM of London Stock Exchange
Personnel: 25
Revenues:
Proximagen provides highly specialized laboratory services for pharmaceutical and biotech companies
to support the discovery and development of novel therapeutic approaches to neurological disorders.
Proximagen's personnel have particular expertise in neurodegenerative conditions, including Parkinson's disease and
Alzheimer's disease.
Profile:
Proximagen is a neuroscience research company focused on drug development for neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.
Mission Statement:
Discoveries for lifetm. We are committed to bringing novel drugs and innovative new treatments to neurodegenerative disease as rapidly as possible, bringing new hope to the patients and value to our shareholders.
Collaborative Opportunities:
Proximagen's collaborative
approach is to leverage its expertise
and predictive pharmacology to acquire compounds that have been developed for the treatment of neurodegenerative disorders.
The company is actively engaged in discussions with leading pharmaceutical companies to in-license such compounds and is
interested in pursuing additional collaborations of this kind.
Registered Address:
Hodgkin Building
Guy's Campus
King's College
London, SE1 1UL
United Kingdom
Company registered in England and Wales with registration number 05333020
|
|
|
|
|
|
|
